Melanoma targeting with DOTA-α-melanocyte-stimulating hormone analogs: Structural parameters affecting tumor uptake and kidney uptake

Journal of Nuclear Medicine

Volumn 46, Issue 5, 2005, Pages 887-895

  Froidevaux, Sylvie ^a,b   Calame Christe, Martine ^a   Tanner, Heidi ^a   Eberle, Alex N ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

melanocyte stimulating hormone; DOTA; Internal radiotherapy; Melanocortin type 1 receptor; Melanoma imaging; Scintigraphy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID NORLEUCYLASPARTYLPHENYLALANYLLYSYLAMIDE; INDIUM 111; INTERMEDIN DERIVATIVE; LYSINE; MELANOCORTIN 1 RECEPTOR; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; ALPHA INTERMEDIN; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SINGLE HETEROCYCLIC RINGS;

ACETYLATION; AMIDATION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG RETENTION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; ELECTRICITY; FEMALE; HYDROPHOBICITY; KIDNEY TUBULE ABSORPTION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR BINDING; ANIMAL; ANTIBODY SPECIFICITY; C57BL MOUSE; CHEMISTRY; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; EVALUATION; KIDNEY; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; SCINTISCANNING; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ALPHA-MSH; ANIMALS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; KIDNEY; MELANOMA; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C57BL; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 20644459733     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Froidevaux S, Eberle AN, Christe M, et al. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer. 2002;98:930-937.
2. 90Y-DOTATOC. Eur J Nucl Med. 2001;28:1552-1554.
3. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439-1447.
4. Froidevaux S, Heppeler A, Eberle AN, et al. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1, 4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinology. 2000;141:3304-3312.
5. Behr TM, Becker WS, Sharkey RM, et al. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med. 1996;37:829-833.
6. Baum RP, Niesen A, Hertel A, et al. Initial clinical results with technetium-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas. Cancer. 1994;73:896-899.
7. Press OW, Shan D, Howell-Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996;56:2123-2129.
8. Boerman OC, Oyen WJ, Corstens FH. Between the scylla and charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med. 2001;28:1447-1449.
9. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201-212.
10. Siegrist W, Solca F, Stutz S, et al. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res. 1989; 49:6352-6358.
11. Bagutti C, Oestreicher M, Siegrist W, Oberholzer M, Eberle AN. Alpha-MSH receptor autoradiography on mouse and human melanoma tissue sections and biopsies. J Recept Signal Transduct Res. 1995;15:427-442.
12. Jiang J, Sharma SD, Fink JL, Hadley ME, Hruby VJ. Melanotropic peptide receptors: membrane markers of human melanoma cells. Exp Dermatol. 1996;5: 325-333.
13. Ghanem GE, Comunale G, Libert A, Vercammen-Grandjean A, Lejeune FJ. Evidence for alpha-melanocyte-stimulating hormone (alpha-MSH) receptors on human malignant melanoma cells. Int J Cancer. 1988;41:248-255.
14. Salazar-Onfray F, Lopez M, Lundqvist A, et al. Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. Br J Cancer. 2002;87:414-422.
15. Froidevaux S, Calame-Christe M, Schuhmacher J, et al. A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med. 2004;45:116-123.
16. 111In-DOTA- rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties. J Nucl Med. 2001;42:1847-1855.
17. Cheng Z, Chen J, Miao Y, Owen NK, Quinn TP, Jurisson SS. Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues. J Med Chem. 2002;45:3048-3056.
18. Froidevaux S, Calame-Christe M, Tanner H, Sumanovski L, Eberle AN. A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med. 2002;43:1699-1706.
19. Fidler IJ. Selection of successive tumour lines for metastasis. Nat New Biol. 1973;242:148-149.
20. Christensen EI, Rennke HG, Carone FA. Renal tubular uptake of protein: effect of molecular charge. Am J Physiol. 1983;244:F436-F441.
21. Deen WM, Satvat B, Jamieson JM. Theoretical model for glomerular filtration of charged solutes. Am J Physiol. 1980;238:F126-F139.
22. Lawrence GM, Brewer DB. Glomerular ultrafiltration and tubular reabsorption of bovine serum albumin and derivatives with increased negative charge in the normal female Wistar rat. Clin Sci. 1984;66:47-54.
23. Kok RJ, Haas M, Moolenaar F, de Zeeuw D, Meijer DK. Drug delivery to the kidneys and the bladder with the low molecular weight protein lysozyme. Renal Fail. 1998;20:211-217.
24. 111In-DTPA-conjugated peptides. Nucl Med Biol. 2001;28:761-768.
25. Duncan JR, Stephenson MT, Wu HP, Anderson CJ. Indium-111- diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res. 1997;57:659-671.
26. Kozlowski L, Wojtukiewicz MZ, Ostrowska H. Cathepsin A activity in primary and metastatic human melanocytic tumors. Arch Dermatol Res. 2000;292:68-71.